FY2027 EPS Estimates for Haemonetics Decreased by Analyst

Haemonetics Co. (NYSE:HAE) – Equities research analysts at Zacks Research reduced their FY2027 earnings estimates for shares of Haemonetics in a report released on Monday, February 3rd. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings of $5.90 per share for the year, down from their previous forecast of $5.91. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.10% and a return on equity of 22.67%.

Several other analysts have also issued reports on the stock. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $112.00 target price on shares of Haemonetics in a report on Tuesday, December 3rd. Barrington Research reiterated an “outperform” rating and issued a $108.00 target price on shares of Haemonetics in a research note on Wednesday, December 4th. Finally, Raymond James raised Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target on the stock in a research report on Friday, November 8th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $108.78.

Haemonetics Trading Down 11.6 %

Shares of Haemonetics stock opened at $62.95 on Wednesday. The stock has a market cap of $3.16 billion, a P/E ratio of 26.12, a P/E/G ratio of 1.07 and a beta of 0.39. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. Haemonetics has a 12-month low of $61.43 and a 12-month high of $97.97. The business’s 50 day moving average is $77.44 and its 200-day moving average is $78.73.

Hedge Funds Weigh In On Haemonetics

Large investors have recently made changes to their positions in the company. Global Alpha Capital Management Ltd. bought a new stake in Haemonetics in the 3rd quarter valued at $806,000. Loomis Sayles & Co. L P boosted its position in shares of Haemonetics by 8.1% in the third quarter. Loomis Sayles & Co. L P now owns 163,856 shares of the medical instruments supplier’s stock valued at $13,171,000 after acquiring an additional 12,310 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Haemonetics by 174.5% in the third quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock valued at $1,362,000 after acquiring an additional 10,774 shares in the last quarter. Westfield Capital Management Co. LP increased its position in Haemonetics by 10.9% during the third quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier’s stock worth $66,206,000 after acquiring an additional 80,783 shares during the period. Finally, Boston Trust Walden Corp raised its stake in Haemonetics by 13.1% in the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock worth $71,500,000 after purchasing an additional 106,114 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.